<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014624</url>
  </required_header>
  <id_info>
    <org_study_id>CS747S-B-U4001</org_study_id>
    <nct_id>NCT01014624</nct_id>
  </id_info>
  <brief_title>Prasugrel/Clopidogrel Maintenance Dose Washout Study</brief_title>
  <official_title>Recovery of Platelet Function Following Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Subjects With Stable Coronary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to describe the cumulative proportion of subjects who
      return to baseline platelet P2Y12 receptor function over time (up to 12 days post last
      maintenance dose) following discontinuation of prasugrel 10 mg daily x 7 days assessed by
      Accumetrics VerifyNow P2Y12 reaction units (PRU) and described by Kaplan Meier curves. The
      primary analysis is descriptive and is intended to provide information relating to the return
      of baseline platelet function following discontinuation of maintenance therapy with either
      prasugrel or clopidogrel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition of Return to Baseline</measure>
    <time_frame>up to 12 days after last dose</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. The results are expressed as cumulative percentage of subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Secondary Definition of Return to Baseline.</measure>
    <time_frame>up to 12 days after last dose</time_frame>
    <description>On the first day of the Washout Period (visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on Primary Definition of Return to Baseline Using the Primary Population.</measure>
    <time_frame>up to 12 days after last dose</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing ws performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on Secondary Definition of Return to Baseline Using the Primary Population.</measure>
    <time_frame>up to 12 days after last dose</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing ws performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on the Primary Definition of Return to Baseline Using the Responder Population.</measure>
    <time_frame>up to 12 days after last dose</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing ws performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on the Secondary Definition of Return to Baseline Using the Responder Population.</measure>
    <time_frame>up to 12 days after the last dose</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to (&lt;=) 20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Platelet Inhibition on Washout Day 1</measure>
    <time_frame>Washout Day 1</time_frame>
    <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Baseline PRU for the Primary Population Using the Primary Definition of Return to Baseline in Relation to the Inhibition of Platelet Aggregation 24 Hours Following the Last Maintenance Dose.</measure>
    <time_frame>up to 12 days after the last dose</time_frame>
    <description>Time to return to baseline PRU (&lt;= 60 units of baseline) dependent upon baseline PRU and platelet % inhibition on Washout Period Day 1 but independent of treatment. The following regression model was derived for predicting number of days to R-to-B PRU where PI(1) represents platelet percentage inhibition on Washout Day 1. Number days to R-to-B PRU derived from: Number days to R-to-B PRU=-3.350+0.079*PI(1)+0.014*baseline PRU.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prasugrel 10mg administered for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel 75mg administered for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>Prasugrel 10mg tablet administered once daily for 7 days.
After a 1-day to 14-day screening period, subjects will receive active treatment with either prasugrel or clopidogrel for 7 days. If a subject has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the subject may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout period depending on the time to reach both of the exit criteria.</description>
    <arm_group_label>prasugrel</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Clopidogrel 75 mg tablet administered once daily for 7 days.
After a 1-day to 14-day screening period, subjects will receive active treatment with either prasugrel or clopidogrel for 7 days. If a subject has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the subject may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout period depending on the time to reach both of the exit criteria.</description>
    <arm_group_label>clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects &gt;/= 18 years and &lt;75 years of age

          -  Weight &gt;/= 60 kg

          -  On aspirin therapy (81 mg to 325 mg daily) at the time of screening and able to
             maintain a consistent aspirin dosing regimen from the baseline visit through the final
             study visit

          -  Subjects who do not have contraindications for a thienopyridine (ie, prasugrel,
             clopidogrel or ticlopidine), and have a history of stable atherosclerosis represented
             by Coronary Artery disease, defined as any of the following:

               -  chronic stable angina

               -  Prior history of acute coronary syndrome (&gt;/= 30 days before screening) including
                  unstable angina or acute myocardial infarction (ST elevation MI [STEMI] or non-ST
                  elevation MI [NSTEMI]), not currently prescribed or currently on thienopyridine
                  therapy;

               -  Previous coronary revascularization including percutaneous transluminal coronary
                  angioplasty (PTCA), stent, or coronary artery bypass grafting (CABG) coronary
                  artery disease (&gt;/= 50% obstruction) in at least one coronary vessel after
                  angiography

          -  Female subjects who meet one of the following:

               -  Women of childbearing potential with a negative serum pregnancy test at screening
                  who are not breast feeding, do not plan to become pregnant during the study, and
                  agree to use an approved method of birth control during the study. Approved
                  methods of birth control are oral, path, injectable or implantable hormonal
                  contraception, intrauterine device, diaphragm plus spermicide, or female condom
                  plus spermicide. Abstinence, partner's use of condoms, and partner's vasectomy
                  are NOT acceptable methods of contraception.

               -  Women who have been postmenopausal for at least 1 year or have had a
                  hysterectomy, bilateral salpingo-oophorectomy, or tubal ligation at least 6
                  months prior to signing the informed consent form.

          -  Subjects with a competent mental condition to provide written informed consent before
             entering the study.

        Exclusion Criteria:

          -  Any other formal indication for the use of a thienopyridine.

          -  Subjects with a history of refractory ventricular arrhythmias.

          -  Subjects with a history of an implantable defibrillator device.

          -  Subjects with a history or evidence of congestive heart failure (New York Heart
             Association [NYHA] Class III or above) within 6 months prior to screening.

          -  Subjects with significant hypertension (systolic blood pressure &gt;180 mmHg or diastolic
             blood pressure &gt;110 mmHg) at either the time of screening or baseline assessment.

          -  Bleeding Risk Exclusion Criteria:

               -  Any known contraindication to treatment with an anticoagulant or antiplatelet
                  agent

               -  Prior history or clinical suspicion of cerebral vascular malformations,
                  intracranial tumor, transient ischemic attack (TIA), or stroke, or recent history
                  (within 3 months) of head trauma

               -  Prior history or presence of significant bleeding disorders (eg, hematemesis,
                  melena, severe or recurrent epistaxis, hemoptysis, hematuria, or intraocular
                  bleeding)

               -  History (within the last 5 years) or presence of gastric ulcers. Previous history
                  of duodenal ulcer is acceptable but must have been successfully surgically or
                  medically treated with no further evidence of disease in the past 6 months (from
                  screening).

               -  Prior history of abnormal bleeding tendency (ie, prolonged bleeding on dental
                  extraction, tonsillectomy, or previous surgical procedure)

               -  Known prior history of thrombocytopenia (platelet count &lt; 100,000/mm³) or
                  thrombocytosis (platelet count &gt; 500,000/mm³) or recent history (within six
                  months) of hemoglobin &lt; 10 mg/dL

               -  Clinically significant out of range values for prothrombin time, activated
                  partial thromboplastin time (aPTT), platelet count, or hemoglobin at screening,
                  in the investigator's opinion

               -  History of major surgery, severe trauma, fracture, or organ biopsy within 3
                  months prior to enrollment

          -  Prior/Concomitant Therapy Exclusion Criteria:

               -  Subjects taking prasugrel, clopidogrel, ticlopidine, cilostazol, dipyridamole,
                  warfarin, heparin, direct thrombin inhibitors, or glycoprotein IIB/IIIa
                  inhibitors =10 days prior to screening or during study participation

               -  The use (or planned use) of fibrinolytic agents within 30 days before screening
                  or during study participation

               -  Subjects receiving treatment with nonsteroidal anti-inflammatory drugs (NSAIDs)
                  or cyclooxygenase-2 (COX-2) inhibitors exceeding 3 doses per week

               -  Subjects receiving proton pump inhibitors (PPIs), eg, (lansoprazole,
                  esomeprazole, omeprazole, pantoprazole, or rabeprazole) =10 days prior to
                  screening or during study participation

          -  General Exclusion Criteria:

               -  Investigator site personnel directly affiliated with the study or immediate
                  family of investigator site personnel directly affiliated with the study.
                  Immediate family is defined as a spouse, parent, child, or sibling, whether
                  biological or legally adopted

               -  Daiichi Sankyo or Eli Lilly employees

               -  Currently enrolled in, or discontinued within the last 30 days prior to baseline
                  from, a clinical study involving an off-label use of an investigational drug or
                  device, or concurrently enrolled in a non-observational clinical study or any
                  other type of medical research judged not to be scientifically or medically
                  compatible with this study

               -  Have previously completed or withdrawn from this study

               -  Women who are known to be pregnant and/or who receive a positive serum pregnancy
                  test result, who have given birth within the past 90 days, and/or who are
                  breastfeeding

               -  Results of clinical laboratory tests at the time of screening that are judged to
                  be clinically significant for the subject, as determined by the investigator

               -  Known allergies or intolerance to aspirin and/or thienopyridines (prasugrel,
                  clopidogrel, or ticlopidine)

               -  Evidence of significant active neuropsychiatric disease, alcohol abuse or drug
                  abuse, in the investigator's opinion

               -  Evidence of active hepatic disease, or any of the following; positive human
                  immunodeficiency virus (HIV) antibodies, positive hepatitis C antibody, positive
                  hepatitis B surface antigen; serum alanine transaminase (ALT), aspartate
                  transaminase (AST), or gamma-glutamyltransferase (GGT) &gt;/= 3 times the upper
                  limit of normal (ULN) laboratory reference range; or bilirubin &gt;/= 2 times the
                  ULN of laboratory reference range at screening

               -  Subjects who are unreliable and unwilling to make themselves available for the
                  duration of the study and who will not abide by the research unit policy and
                  procedure and study restrictions

          -  Subjects who have had an angiogram &lt;/= 7 days before randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center Shands Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medpace Clinical Pharmacology Unit</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Clinical Research Center</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <results_first_submitted>May 31, 2011</results_first_submitted>
  <results_first_submitted_qc>August 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2011</results_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thienopyridine</keyword>
  <keyword>pharmacologic action</keyword>
  <keyword>prasugrel</keyword>
  <keyword>clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at 4 sites in the US from 23 February 2010 to 04 May 2010 and 56 subjects were randomized into the study. The study population consisted of male and female aspirin-treated subjects with stable coronary artery disease, 18 to 75 years of age.</recruitment_details>
      <pre_assignment_details>Following a 1-day to 14-day Screening Period, eligible subjects were randomized in a 1:1 ratio to either prasugrel or clopidogrel at Visit 2 (the first day of the Active Treatment Period).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prasugrel</title>
          <description>Prasugrel 10 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel</title>
          <description>Clopidogrel 75 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prasugrel</title>
          <description>Prasugrel 10 mg tablet daily</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel</title>
          <description>Clopidogrel 75 mg tablet daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="8.45" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="62.3" spread="8.10" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="59.80" spread="8.56" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="20" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="45" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="27" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="55" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="5" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="10" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="22" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="44" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.3" spread="15.13" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="90.8" spread="14.41" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="94.1" spread="15.02" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174.1" spread="8.20" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="173.5" spread="9.00" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="173.8" spread="8.52" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="1" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="27" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="55" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.0" spread="4.07" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="30.3" spread="5.34" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="31.2" spread="4.76" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="10" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="17" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently Smoke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="6" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="16" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Formerly Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="23" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never used alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="5" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="8" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently use alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="18" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="37" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Formerly used alcohol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="4" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Does not have diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="16" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="34" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Has diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B2" value="11" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="B3" value="22" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition of Return to Baseline</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. The results are expressed as cumulative percentage of subjects.</description>
        <time_frame>up to 12 days after last dose</time_frame>
        <population>Subjects in Primary Population (Pop.) using primary definition of R-to-B. Primary Pop. included subjects entered Washout Period and had platelet function data at both baseline and Washout Period Day 1. Primary definition of R-to-B was (Baseline PRU-PRU) less than or equal to 60 units.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 10 mg Daily</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel 75 mg Daily</title>
          </group>
        </group_list>
        <measure>
          <title>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Primary Definition of Return to Baseline</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. The results are expressed as cumulative percentage of subjects.</description>
          <population>Subjects in Primary Population (Pop.) using primary definition of R-to-B. Primary Pop. included subjects entered Washout Period and had platelet function data at both baseline and Washout Period Day 1. Primary definition of R-to-B was (Baseline PRU-PRU) less than or equal to 60 units.</population>
          <units>cumulative percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>return to baseline PRU by washout day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="30.8" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>return to baseline PRU by washout day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="53.9" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>return to baseline PRU by washout day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="84.6" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>return to baseline PRU by washout day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.9" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="96.2" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>return to baseline PRU by washout day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="96.2" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>return to baseline PRU by washout day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="100.0" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Secondary Definition of Return to Baseline.</title>
        <description>On the first day of the Washout Period (visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%</description>
        <time_frame>up to 12 days after last dose</time_frame>
        <population>Subjects in Primary Pop. using secondary definition of return to baseline. Primary Population included subjects entered the Washout Period and had platelet function data at both baseline and Washout Period Day 1. Secondary definition of return to baseline was (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 10mg Daily</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel 75mg Daily</title>
          </group>
        </group_list>
        <measure>
          <title>The Time to Return to Baseline Platelet Function as Assessed by P2Y12 Reaction Units (PRU) Using the Accumetrics VerifyNOW P2Y12 Device Based on the Secondary Definition of Return to Baseline.</title>
          <description>On the first day of the Washout Period (visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%</description>
          <population>Subjects in Primary Pop. using secondary definition of return to baseline. Primary Population included subjects entered the Washout Period and had platelet function data at both baseline and Washout Period Day 1. Secondary definition of return to baseline was (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%</population>
          <units>cumulative percent returned to baseline</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>returned to baseline PRU by washout day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="30.8" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>returned to baseline PRU by washout day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="53.9" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>returned to baseline PRU by washout day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="80.8" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>returned to baseline PRU by washout day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="88.5" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>returned to baseline PRU by washout day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="96.2" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>returned to baseline PRU by washout day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="100.0" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on Primary Definition of Return to Baseline Using the Primary Population.</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing ws performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
        <time_frame>up to 12 days after last dose</time_frame>
        <population>Subjects in Primary Population using primary definition of return to baseline. Primary population included subjects entered the Washout Period and had platelet function data at both baseline and Washout Period Day 1. Primary definition of return to baseline was (Baseline PRU-PRU) less than or equal to 60 units</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 10 mg tablet daily</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel 75 mg tablet daily</description>
          </group>
        </group_list>
        <measure>
          <title>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on Primary Definition of Return to Baseline Using the Primary Population.</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing ws performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
          <population>Subjects in Primary Population using primary definition of return to baseline. Primary population included subjects entered the Washout Period and had platelet function data at both baseline and Washout Period Day 1. Primary definition of return to baseline was (Baseline PRU-PRU) less than or equal to 60 units</population>
          <units>day 50%, 75%, 90% returned to baseline</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Washout day 50% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="3" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 75% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 90% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="6" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on Secondary Definition of Return to Baseline Using the Primary Population.</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing ws performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
        <time_frame>up to 12 days after last dose</time_frame>
        <population>Subjects in Primary Population using secondary definition of return to baseline. Primary Population included subjects entered Washout Period and had platelet function data at both baseline and Washout Period Day 1. Secondary definition of return to baseline was (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 10mg Daily</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel 75mg Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on Secondary Definition of Return to Baseline Using the Primary Population.</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing ws performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
          <population>Subjects in Primary Population using secondary definition of return to baseline. Primary Population included subjects entered Washout Period and had platelet function data at both baseline and Washout Period Day 1. Secondary definition of return to baseline was (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%</population>
          <units>day 50%, 75%, 90% returned to baseline</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Washout day 50% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="3" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 75% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 90% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on the Primary Definition of Return to Baseline Using the Responder Population.</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing ws performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
        <time_frame>up to 12 days after last dose</time_frame>
        <population>Subjects in Responder Pop. using primary definition of R-to-B. Primary Pop. included subjects entered Washout Period and had platelet function data at baseline and Washout Day 1. Responder Pop. was Primary Pop. excluding poor pharmacodynamic responders. Primary definition of R-to-B was (Baseline PRU-PRU) less than or equal to 60 units</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 10mg Daily</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel 75mg Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on the Primary Definition of Return to Baseline Using the Responder Population.</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing ws performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%.</description>
          <population>Subjects in Responder Pop. using primary definition of R-to-B. Primary Pop. included subjects entered Washout Period and had platelet function data at baseline and Washout Day 1. Responder Pop. was Primary Pop. excluding poor pharmacodynamic responders. Primary definition of R-to-B was (Baseline PRU-PRU) less than or equal to 60 units</population>
          <units>day 50%, 75%, 90% returned to baseline</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Washout day 50% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 75% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 90% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="6" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on the Secondary Definition of Return to Baseline Using the Responder Population.</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to (&lt;=) 20%</description>
        <time_frame>up to 12 days after the last dose</time_frame>
        <population>Subjects in Responder Pop. using secondary definition of R-to-B. Primary Pop. included subjects entered Washout Period and had platelet function data at both baseline and Washout Period Day 1. Responder Pop. was primary pop. excluding poor pharmacodynamic responders. Secondary definition of R-to-B was (Baseline PRU-PRU)/ (Baseline PRU) &lt;= 20%</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 10mg Daily</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel 75mg Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Day at Which 50%, 75%, and 90% of Subjects Returned to Baseline Platelet Function Based on the Secondary Definition of Return to Baseline Using the Responder Population.</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to (&lt;=) 20%</description>
          <population>Subjects in Responder Pop. using secondary definition of R-to-B. Primary Pop. included subjects entered Washout Period and had platelet function data at both baseline and Washout Period Day 1. Responder Pop. was primary pop. excluding poor pharmacodynamic responders. Secondary definition of R-to-B was (Baseline PRU-PRU)/ (Baseline PRU) &lt;= 20%</population>
          <units>day50%, 75%, 90% returned to baseline</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Washout day 50% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 75% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="6" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Washout day 90% returned to baseline PRU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="7" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Platelet Inhibition on Washout Day 1</title>
        <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%</description>
        <time_frame>Washout Day 1</time_frame>
        <population>Subjects in the Primary Population. The Primary Population included subjects who entered the Washout Period and had platelet function testing data at both baseline (Visit 2) and Washout Period Day 1 (Visit 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 10mg Daily</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel 75mg Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Platelet Inhibition on Washout Day 1</title>
          <description>On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the subject met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%</description>
          <population>Subjects in the Primary Population. The Primary Population included subjects who entered the Washout Period and had platelet function testing data at both baseline (Visit 2) and Washout Period Day 1 (Visit 3).</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3" spread="11.78" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="35.4" spread="23.35" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Baseline PRU for the Primary Population Using the Primary Definition of Return to Baseline in Relation to the Inhibition of Platelet Aggregation 24 Hours Following the Last Maintenance Dose.</title>
        <description>Time to return to baseline PRU (&lt;= 60 units of baseline) dependent upon baseline PRU and platelet % inhibition on Washout Period Day 1 but independent of treatment. The following regression model was derived for predicting number of days to R-to-B PRU where PI(1) represents platelet percentage inhibition on Washout Day 1. Number days to R-to-B PRU derived from: Number days to R-to-B PRU=-3.350+0.079*PI(1)+0.014*baseline PRU.</description>
        <time_frame>up to 12 days after the last dose</time_frame>
        <population>Subjects in the Primary Population. The Primary Population included subjects who entered the Washout Period and had platelet function testing data at both baseline (Visit 2) and Washout Period Day 1 (Visit 3). The primary definition of return to baseline was (Baseline PRU-PRU) less than or equal to 60 units.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel 10mg Daily</title>
          </group>
          <group group_id="O2">
            <title>Clopidogrel 75mg Daily</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Baseline PRU for the Primary Population Using the Primary Definition of Return to Baseline in Relation to the Inhibition of Platelet Aggregation 24 Hours Following the Last Maintenance Dose.</title>
          <description>Time to return to baseline PRU (&lt;= 60 units of baseline) dependent upon baseline PRU and platelet % inhibition on Washout Period Day 1 but independent of treatment. The following regression model was derived for predicting number of days to R-to-B PRU where PI(1) represents platelet percentage inhibition on Washout Day 1. Number days to R-to-B PRU derived from: Number days to R-to-B PRU=-3.350+0.079*PI(1)+0.014*baseline PRU.</description>
          <population>Subjects in the Primary Population. The Primary Population included subjects who entered the Washout Period and had platelet function testing data at both baseline (Visit 2) and Washout Period Day 1 (Visit 3). The primary definition of return to baseline was (Baseline PRU-PRU) less than or equal to 60 units.</population>
          <units>days to return to baseline PRU</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="3.7" spread="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Beginning with screening, adverse events (AEs) were assessed at every visit. All AEs occuring after subject signed informed consent and up to 14 days after last dose of study drug were recorded</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prasugrel 10 mg/Daily</title>
        </group>
        <group group_id="E2">
          <title>Clopidogrel 75mg/ Daily</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>eyelid oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Adominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>increased tendency to bruise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Baker</name_or_title>
      <organization>Daiichi Sankyo, Inc.</organization>
      <phone>973-944-2712</phone>
      <email>bbaker@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

